Merck & Co hopes for foothold in early TNBC after Keytruda t...

Merck & Co has unveiled data from its immunotherapy Keytruda that could allow it to gain a foothold in the tough-to-treat triple negative breast cancer (TNBC) indication, and potentiall

MHRA says Avastin can be used for AMD despite Bayer, Novarti...

Bayer’s Vitrakvi is first tumour-agnostic drug approved in E...

Roche's Gazyva wins Breakthrough Therapy status for lupus ne...

Roche’s Gazyva has won Breakthrough Therapy status for its potential new use in the autoimmune disease lupus nephritis, as the Swiss pharma attempts to breathe new life into the drug curren

As 'big three' oncology meds lose sales, Roche looks to file...

A subcutaneous formulation of Roche’s Perjeta and Herceptin breast cancer drugs works as well as an original intravenous (IV) version, a study has shown.

Roche preps filings for satralizumab in rare disease NMOSD